BIIB-053

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameBIIB-053

Drug Alias NameDR6 antagonistsDeath receptor-6 antagonistsBIIB-053

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTumor necrosis factor receptor superfamily member 21 antagonists

TargetsTumor necrosis factor receptor superfamily member 21

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBiogen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBiogen Inc

Active IndicationsN/A

Inactive IndicationsMultiple Sclerosis

ATC CodeN/A